Outpatient Uterine Polypectomy More Cost-Effective

This article originally appeared here.
Share this content:
Outpatient Uterine Polypectomy More Cost-Effective
Outpatient Uterine Polypectomy More Cost-Effective

(HealthDay News) -- For women with abnormal uterine bleeding and hysteroscopically diagnosed endometrial polyps, outpatient treatment is more cost-effective than inpatient treatment, according to research published online May 25 in BJOG: An International Journal of Obstetrics and Gynaecology.

Lavanya Diwakar, from the University of Birmingham in the United Kingdom, and colleagues conducted a cost-effectiveness analysis of outpatient uterine polypectomy versus standard inpatient treatment under general anesthesia. Data were included for 507 women with abnormal uterine bleeding and hysteroscopically diagnosed endometrial polyps. Within the allocated setting, clinicians were free to choose the technique for polypectomy.

The researchers found that inpatient treatment was slightly more effective than outpatient treatment, but costs were higher, resulting in relatively high incremental cost-effectiveness ratios. Compared with outpatient treatment, inpatient treatment cost an additional £9,421 per successfully treatment patient, and £1,099,167 per additional quality-adjusted life-year (QALY) gained at six months. These costs were £22,293 per additional effectively treated patient and £445,867 per additional QALY gained at 12 months.

"Outpatient treatment of uterine polyps associated with abnormal uterine bleeding appears to be more cost-effective than inpatient treatment at willingness-to-pay thresholds acceptable to the National Health Service," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths